Kras gene mutation analysis
Jump to navigation
Jump to search
Pharmacology
Indications
- defects in KRAS are a cause of
- acute myelogenous leukemia
- juvenile myelomonocytic leukemia
- Noonan syndrome 3
- cardiofaciocutaneous syndrome
- KRAS mutations are involved in cancer development, colorectal carcinoma[4]
- lung cancer[4]
- pancreatic cancer[4]
Laboratory
- LOINC: 21702-6, 21704-4, 53620-1
More general terms
More specific terms
Additional terms
Component of
References
- ↑ Lievre A et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008 Jan 20; 26:374. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18202412
- ↑ Patil DT, Fraser CR, Plesec TP. KRAS testing and its importance in colorectal cancer. Curr Oncol Rep. 2010 May;12(3):160-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20425075
Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010 Mar;32(3):437-53. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20399983 - ↑ KRAS Mutation Detection Laboratory Test Directory ARUP: http://www.aruplab.com/guides/ug/tests/0040248.jsp
- ↑ 4.0 4.1 4.2 4.3 Sumnners C What's new in KRAS mutation research? MD Anderson 2024. April 4 https://www.mdanderson.org/cancerwise/what-s-new-in-kras-mutation-research-.h00-159696756.html